Azzad Asset Management Inc /Adv Exact Sciences Corp Transaction History

Azzad Asset Management Inc /Adv

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 01, 2024	SELL	$47.19 - $70.77 $199,566 - $299,286	-4,229 Closed	0 $0
Q4 2022 Apr 01, 2024	SELL	$30.35 - $53.15 $161,249 - $282,385	-5,313 Reduced 55.68%	4,229 $209 Million
Q3 2022 Apr 01, 2024	SELL	$31.97 - $49.37 $419,350 - $647,586	-13,117 Reduced 57.89%	9,542 $430 Million
Q2 2022 Apr 01, 2024	BUY	$35.61 - $76.23 $132,219 - $283,041	3,713 Added 19.6%	22,659 $998 Million
Q1 2022 Apr 01, 2024	BUY	$57.56 - $82.54 $49,098 - $70,406	853 Added 4.71%	18,946 $1.32 Billion
Q4 2021 Apr 01, 2024	BUY	$72.5 - $100.68 $60,392 - $83,866	833 Added 4.83%	18,093 $1.41 Billion
Q3 2021 Apr 01, 2024	BUY	$90.24 - $124.05 $1.4 Million - $1.92 Million	15,482 Added 870.75%	17,260 $1.65 Billion
Q2 2021 Apr 01, 2024	BUY	$93.66 - $139.27 $166,527 - $247,622	1,778 New	1,778 $221 Million
Q1 2020 Apr 01, 2024	SELL	$37.9 - $104.44 $171,080 - $471,442	-4,514 Closed	0 $0
Q4 2019 Apr 01, 2024	BUY	$77.66 - $99.74 $11,571 - $14,861	149 Added 3.41%	4,514 $405 Million
Q3 2019 Apr 01, 2024	BUY	$90.37 - $122.49 $394,465 - $534,668	4,365 New	4,365 $387 Million

667

162M

2.58M

2.19M

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $9.91B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

Get notified when there are updates to the investment portfolio of Azzad Asset Management Inc /Adv, based on Form 13F filings with the SEC.

Stay updated on Azzad Asset Management Inc /Adv with notifications on news.